NCT05152147 2026-04-17
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3 Active not recruiting
Clinical Trials
11 trialsNCT07405476 2026-04-17
Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment
Emory University
Phase 2 Recruiting
NCT06324357 2026-04-15
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Boehringer Ingelheim
Phase 1/2 Recruiting
NCT04164199 2026-04-14
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
BeOne Medicines
Phase 3 Active not recruiting
NCT06695845 2026-04-09
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
Phase 2 Recruiting
NCT07494448 2026-03-27
JAZMINE
MedSIR
Phase 1/2 Not yet recruiting
NCT06282575 2026-03-24
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Jazz Pharmaceuticals
Phase 3 Recruiting
NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT07102381 2026-03-12
EmpowHER 208
Jazz Pharmaceuticals
Phase 2 Recruiting
NCT06435429 2026-02-10
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Jazz Pharmaceuticals
Phase 3 Recruiting
NCT07176312 2026-02-04
ZANGEA
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting